M. Prah

发表

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI

D. Mankoff, Lucy Hanna, A. Sorensen, 2016, Clinical Cancer Research.

Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project

B Erickson, P E Kinahan, T L Chenevert, 2018, American Journal of Neuroradiology.

Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

P. LaViolette, W. Mueller, M. Malkin, 2013, Neuro-oncology.

Value of Dynamic Contrast Perfusion MRI to Predict Early Response to Bevacizumab in Newly Diagnosed Glioblastoma: Results from ACRIN 6686 Multi-Center Trial.

J. Boxerman, K. Schmainda, D. Barboriak, 2020, Neuro-oncology.

Magnetic Resonance Imaging Mapping of Brain Tumor Burden: Clinical Implications for Neurosurgical Management: Case Report

W. Mueller, E. Cochran, K. Schmainda, 2021, Neurosurgery open.

Presumed Hydrogen Sulfide-mediated Neurotoxicity After Streptococcus Anginosus Group Meningitis

K. Schmainda, S. Verma, Rachel M. Landisch, 2013, The Pediatric infectious disease journal.

PREVALENCE OF PHARYNgEAL CARRIAgE OF KINGELLA KINGAE IN YOUNg CHILDREN AND RISK FACTORS FOR COLONIZATION

K. Schmainda, S. Verma, Rachel M. Landisch, 2013 .

Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low–Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors

J. Boxerman, K. Schmainda, C. Quarles, 2019, American Journal of Neuroradiology.

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

W. Mueller, M. Malkin, K. Schmainda, 2014, Neuro-oncology.

Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma

W. Mueller, E. Cochran, K. Schmainda, 2022, Frontiers in Oncology.

Basal Ganglia Iron Content Increases with Glioma Severity Using Quantitative Susceptibility Mapping: A Potential Biomarker of Tumor Severity

Jongho Lee, K. Schmainda, J. Connelly, 2022, Tomography.

Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial

J. Boxerman, K. Schmainda, D. Barboriak, 2019, American Journal of Neuroradiology.

Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes

W. Mueller, K. Schmainda, M. Siker, 2020, International journal of radiation oncology, biology, physics.

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy

D. Mankoff, Lucy Hanna, K. Schmainda, 2018, PloS one.

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma

J. Kalpathy-Cramer, Jayashree Kalpathy-Cramer, S. Stufflebeam, 2015, American Journal of Neuroradiology.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

A Gregory Sorensen, Kathleen M Schmainda, Daniel P Barboriak, 2015, Neuro-oncology.

Effects of perfusion on diffusion changes in human brain tumors

P. LaViolette, W. Mueller, M. Malkin, 2013, Journal of magnetic resonance imaging : JMRI.

Multi‐Site Concordance of Diffusion‐Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness

K. Iczkowski, T. Yankeelov, Wei Huang, 2021, Journal of magnetic resonance imaging : JMRI.

The Effect of Pulse Sequence Parameters and Contrast Agent Dose on Percentage Signal Recovery in DSC-MRI: Implications for Clinical Applications

J. Boxerman, K. Schmainda, E. Paulson, 2013, American Journal of Neuroradiology.

Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network

Thomas E. Yankeelov, Wei Huang, Jayashree Kalpathy-Cramer, 2017, Journal of medical imaging.

Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics

Wade M Mueller, Kathleen M Schmainda, W. Mueller, 2017, Journal of Neuro-Oncology.

Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO)

Thomas E. Yankeelov, Chengyue Wu, Mark Muzi, 2019, Tomography.

1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies

Hua Yang, M. Tallman, R. Stone, 2014 .

Pulsed reduced dose rate radiotherapy in conjunction with bevacizumab significantly extends survival over bevacizumab alone in recurrent high-grade glioma.

W. Mueller, K. Schmainda, M. Siker, 2020, International journal of radiation oncology, biology, physics.

Protocol: Validation of a Low Moving Toward a Consensus DSC-MRI

K. Schmainda, C. Quarles, B. Anderies, 2019 .

Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies

Thomas E. Yankeelov, Mark Muzi, Michael Boss, 2017, Journal of medical imaging.

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma

Jayashree Kalpathy-Cramer, S. Stufflebeam, K. Schmainda, 2015, American Journal of Neuroradiology.